BCL2 and neoplasm: miR-192 was previously reported to inhibit the liver metastasis of colon cancer through targeting Bcl-2, Zeb-2, and VEGFA [31], to suppress tumor progression in renal cell carcinoma [32], to inhibit cell proliferation and induce apoptosis in lung cancer [33], and to be a biomarker of distant metastasis in gastric cancer [34].